Erythrocyte Membrane-Camouflaged Hemin-Based Nanoplatform for Radiotherapy of Glioblastoma

Glioblastoma, accounting for 44% of all malignant brain tumors, is characterized by a dismal prognosis due to high mortality, recurrence, and limited survival time. Current standard treatment, radiotherapy, is resistant to the tumor hypoxic microenvironment, which reduces the effect of radiotherapy. Here, we present a nanoplatform, PLGA-Hemin@RBCM (PHR), which leverages the catalase mimetic activity of hemin to convert tumor-elevated H₂O₂ into oxygen and hydroxyl radicals, improving tumor oxygenation and enhancing radiotherapy sensitivity. The PEG-PLGA nanomicelle delivery platform improves the biocompatibility and stability of the drug and delays the release of the drug. Camouflaging the nanoparticles with red blood cell membranes not only avoids immune clearance but also prolongs circulation time and enhances tumor accumulation via the EPR effect. In vitro and in vivo studies demonstrate the efficacy of our nanoplatform, offering a promising therapeutic strategy for glioblastoma management in the clinic.